Alexander I Spira, MD, PhD, FACP - presents key study at ASCO 2022 - Durable Responses in Pretreated KRAS G12C–Mutant NSCLC

Adagrasib Elicits Deep and Durable Responses in Pretreated KRAS G12C–Mutant NSCLC

https://www.onclive.com/view/adagrasib-elicits-deep-and-durable-responses-in-pretreated-kras-g12c-mutant-nsclc

At the meeting, Alexander I. Spira, MD, PhD, FACP, co-director of Virginia Cancer Specialists Research Institute, director of the Thoracic and Phase I Program, and clinical assistant professor at Johns Hopkins School of Medicine, presented data as of October 15, 2021, from the registrational phase 2 cohort A study, which was simultaneously published in the New England Journal of Medicine.